Coral Laboratories Ltd

Coral Labs. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Coral Laboratories Ltd

₹ 665 -0.65%
03 Jul 4:01 p.m.
corallab.com BSE: 524506
About

Incorporated in 1994 and headquartered in Mumbai – India Coral Laboratories Ltd is into the Manufacturing of Pharmaceutical formulations. The company manufactures Generic – Branded, Herbal Medicines, etc. in the product categories of Non-Sterile, Sterile, Nutraceuticals, Otc + Lifestyle, and it exports its products mainly to Ethiopia and other parts of the world.[1]

Key Points

Product Portfolio: [1]
The four important product categories include:
Non-Sterile: This comprises Capsules, Tablets, Dry syrup, etc. in Antibiotics/Anti-bacterial, Anti-fungal, Gastro-Intestinal Drugs, etc.
Sterile: This category includes Injectables, Eye Drops, Ear Drops, Nasal Sprays, and large volume Parenteral.
Nutraceuticals: The company provides a wide range of nutraceutical products such as dietary supplements, herbal / phytochemicals, multi-vitamins, and nutrients.
OTC+Lifestyle: The company provides products in the range of Female Hygiene, Contraceptives, Medical Devices, Skin Care, Infant & Child Care products, and Herbal products.

Website BSE
  • Market Cap ₹ 237 Cr.
  • Current Price ₹ 665
  • High / Low ₹ 693 / 230
  • Stock P/E 14.9
  • Book Value ₹ 497
  • Dividend Yield 0.00 %
  • ROCE 12.6 %
  • ROE 9.58 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company is almost debt free.
  • Company is expected to give good quarter

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • The company has delivered a poor sales growth of -1.69% over past five years.
  • Company has a low return on equity of 6.55% over last 3 years.
  • Earnings include an other income of Rs.6.47 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Formulations

Edit Columns
Loading peers table ...

Quarterly Results

Figures in Rs. Crores

Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024
27.82 23.79 18.42 13.33 20.08 16.25 25.70 24.73 11.44 13.55 23.15 18.08 28.89
25.64 17.54 17.43 13.42 19.03 15.52 21.39 23.88 13.52 11.81 17.00 15.98 22.64
Operating Profit 2.18 6.25 0.99 -0.09 1.05 0.73 4.31 0.85 -2.08 1.74 6.15 2.10 6.25
OPM % 7.84% 26.27% 5.37% -0.68% 5.23% 4.49% 16.77% 3.44% -18.18% 12.84% 26.57% 11.62% 21.63%
2.06 1.50 0.85 0.94 2.49 2.03 2.21 1.54 1.16 1.29 1.81 1.37 2.00
Interest 0.03 0.06 0.02 0.01 0.05 0.10 0.11 0.11 0.02 -0.00 -0.00 -0.00 -0.00
Depreciation 0.50 0.50 0.49 0.51 0.50 0.50 0.50 0.50 0.68 0.55 0.44 0.49 0.50
Profit before tax 3.71 7.19 1.33 0.33 2.99 2.16 5.91 1.78 -1.62 2.48 7.52 2.98 7.75
Tax % 53.10% 19.33% 66.92% 27.27% 14.72% 26.39% 17.26% 51.69% 45.06% 26.21% 20.21% 27.52% 25.16%
1.74 5.80 0.45 0.25 2.55 1.59 4.89 0.86 -0.89 1.84 6.00 2.16 5.79
EPS in Rs 4.87 16.23 1.26 0.70 7.14 4.45 13.69 2.41 -2.49 5.15 16.79 6.05 16.21
Raw PDF

Profit & Loss

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
42 51 59 77 95 92 91 71 97 76 78 84
34 41 47 60 72 77 79 65 81 67 74 67
Operating Profit 8 10 12 16 23 15 12 5 16 8 4 16
OPM % 18% 20% 21% 21% 24% 17% 14% 8% 16% 11% 5% 19%
1 1 3 3 3 4 5 6 4 6 7 6
Interest 0 0 0 0 0 0 0 0 0 0 0 -0
Depreciation 1 1 3 2 2 2 2 2 2 2 2 2
Profit before tax 8 10 12 17 25 18 16 9 18 12 8 21
Tax % 20% 21% 22% 29% 34% 31% 34% 22% 23% 24% 22% 24%
6 8 10 12 16 12 10 7 14 9 6 16
EPS in Rs 16.88 22.03 26.79 34.71 45.63 34.85 28.61 19.96 37.93 25.33 18.05 44.20
Dividend Payout % 9% 9% 9% 9% 11% 6% 7% -0% -0% -0% -0% -0%
Compounded Sales Growth
10 Years: 5%
5 Years: -2%
3 Years: -5%
TTM: 7%
Compounded Profit Growth
10 Years: 7%
5 Years: 9%
3 Years: 6%
TTM: 148%
Stock Price CAGR
10 Years: 19%
5 Years: 26%
3 Years: 15%
1 Year: 170%
Return on Equity
10 Years: 10%
5 Years: 7%
3 Years: 7%
Last Year: 10%

Balance Sheet

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity Capital 4 4 4 4 4 4 4 4 4 4 4 4
Reserves 40 47 56 67 106 113 110 112 133 152 151 174
1 0 1 0 2 2 1 6 6 6 -0 -0
14 10 12 19 20 22 21 23 25 28 20 28
Total Liabilities 58 60 72 89 131 140 136 144 168 190 174 206
21 20 19 18 18 22 23 23 21 24 25 24
CWIP -0 -0 -0 -0 0 -0 -0 -0 0 2 -0 -0
Investments 1 1 1 5 39 45 28 25 33 46 41 50
36 40 52 67 74 73 84 97 112 118 108 132
Total Assets 58 60 72 89 131 140 136 144 168 190 174 206

Cash Flows

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
0 1 0 5 11 13 -1 -4 1 6 13 -5
0 1 -0 -3 -10 -13 3 -2 -0 -6 -3 1
0 -0 -0 -0 0 -3 -1 4 0 0 -6 0
Net Cash Flow 1 2 -0 2 1 -2 1 -2 1 0 4 -4

Ratios

Figures in Rs. Crores

Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 93 109 152 132 117 125 122 178 148 184 109 123
Inventory Days 124 97 110 110 155 120 116 176 158 169 100 149
Days Payable 97 61 66 80 75 87 91 129 108 81 34 130
Cash Conversion Cycle 120 145 196 162 197 157 146 225 198 272 176 142
Working Capital Days 143 159 202 181 172 168 177 241 202 251 221 295
ROCE % 19% 21% 22% 27% 28% 16% 13% 8% 13% 7% 5%

Shareholding Pattern

Numbers in percentages

2 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51% 71.51%
0.42% 0.42% 0.42% 0.42% 0.42% 0.14% 0.14% 0.14% 0.14% 0.14% 0.14% 0.14%
28.07% 28.07% 28.07% 28.07% 28.07% 28.34% 28.34% 28.34% 28.35% 28.34% 28.35% 28.35%
No. of Shareholders 4,0204,2374,4254,3884,3174,2184,1104,0464,0403,9814,0054,098

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports